The FDA safety communication issued a warning to the general public and the medical community that the agency is monitoring the side effects of SGLT2 inhibitors to determine whether changes need to be made in the prescribing protocol of the drug. The FDA wants patients to report any unusual side effects after starting the drug… read more
Knowledge Experience Compassion Service
Helping injured people and their families for more than 50 years.
